Noxxon's Morich to leave in August

Germany's Noxxon Pharma has announced that CEO Frank Morich will leave the company effective Aug. 15 to take up the position executive VP, international operations, at Takeda Pharmaceutical Company Limited. Iain Buchanan will assume the role of interim CEO  and will support the board during its search for a permanent replacement. Release

Bind Biosciences has appointed Ed Schnipper as chief medical officer. Release

Michael Tremblay has been appointed president of the Canadian subsidiary of Astellas Pharma. His predecessor, Fumiaki Sakurai, will return to Japan to assume a new role in the company's Asia International Division. Release

David Price, executive VP and CFO at Cornerstone Therapeutics, is leaving the company. He will assume the CFO position at another company.  Release

Cleveland BioLabs has appointed Michael Paterno as director of clinical operations. Release

Avrio Biopharmaceuticals has named David Gelber as the director of manufacturing. Release

Peter Strumph has joined Codexis as senior VP, commercial operations, a new position. Release

Clinuvel Pharmaceuticals has announced that Stan McLiesh will assume the role of non-executive chairman of Clinuvel. In addition, Brenda Shanahan will preside over the audit and risk committee. Release

PharmaGap has appointed Ian Malone to its board of directors. Malone has extensive finance and biotech industry experience and will bring key insights to the board of PharmaGap as it proceeds toward clinical trials and out-licensing of its lead cancer drug GAP-107B8. Release

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.